Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulisobenzone is an organic compound belonging to the benzophenones class, primarily used as a sunscreen agent. It functions as a UV filter, absorbing both UVA and UVB radiation to protect the skin from sun-induced damage such as sunburn, premature aging, and increased risk of skin cancer. The mechanism involves chemical absorption of ultraviolet light energy by the molecule’s conjugated system; this energy is then dissipated harmlessly as thermal energy when the molecule returns to its ground state. Sulisobenzone is approved for use in concentrations up to 10% in topical formulations by regulatory agencies such as the FDA and Health Canada. It does not significantly penetrate human skin but may enhance penetration of other chemicals. Sulisobenzone is widely used in sunscreens and personal care products[1][2][3][6]. Some sources refer to potential for mild skin or eye irritation with use; there are also ongoing studies regarding possible endocrine-disrupting effects, though evidence remains limited[4][6]. No specific developer or manufacturer names were identified in available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulisobenzone.